MIRM
HealthcareMirum Pharmaceuticals, Inc.
$75.56
$-2.51 (-3.22%)
Jan 5, 2026
Price History (1Y)
Analysis
Mirum Pharmaceuticals, Inc. operates in the healthcare sector within the biotechnology industry and has a significant scale with a market capitalization of $3.91 billion, revenue of $471.79 million, and 355 employees. The company's financial health is characterized by negative profitability metrics, including an operating margin of 2.0%, profit margin of -8.8%, return on equity of -15.8%, and return on assets of -3.6%. However, the balance sheet shows a substantial cash position of $375.55 million and debt of $318.76 million, resulting in a debt to equity ratio of 109.15. Mirum Pharmaceuticals' valuation is marked by a forward P/E ratio of -390.83, which indicates that the company's current stock price is not accurately reflected by its expected earnings growth. The revenue growth rate is relatively high at 47.2% year-over-year, but there are no dividend payments as indicated by a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Visit website →Key Statistics
- Market Cap
- $3.91B
- P/E Ratio
- N/A
- 52-Week High
- $82.58
- 52-Week Low
- $36.88
- Avg Volume
- 688.04K
- Beta
- 0.49
Company Info
- Industry
- Biotechnology
- Exchange
- NGM
- Country
- United States
- Employees
- 355